Prosecution Insights
Last updated: May 29, 2026
Application No. 18/020,323

Bee Product Extracts, Methods of Production, and Uses Thereof

Non-Final OA §112
Filed
Feb 08, 2023
Priority
Aug 11, 2020 — NE 767031 +1 more
Examiner
MI, QIUWEN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Quantum Technologies Limited
OA Round
2 (Non-Final)
68%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
1076 granted / 1577 resolved
+8.2% vs TC avg
Strong +50% interview lift
Without
With
+49.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
33 currently pending
Career history
1612
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
72.7%
+32.7% vs TC avg
§102
15.5%
-24.5% vs TC avg
§112
7.2%
-32.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1577 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is to replace the office action sent out on 12/16/25, as wrong set of claims was examined. Election/Restrictions Claims 1, 4-9, 18, 21, and 35-39 are pending. Applicant’s election without traverse of Group I, claims 1, 4-9, 18, 20, 21, and 35-39 in the reply filed on 11/19/25 is acknowledged. Claims 20, 22, 23, 25, 27, and 31 are cancelled. Election was made without traverse in the reply filed on 11/19/25. The species election requirement is hereby withdrawn. Claims 1, 4-9, 18, 21, and 35-39 are examined on the merits. Claim Rejections –35 USC § 112, 2nd The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 4-9, 18, 21, and 35-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims recite the following limitations, and there are insufficient antecedent basis for these limitations in the claims: “the pH” in claim 1, at lines 6 and 10; “the resin” in claim 7, at line 2; “the sugar content” in claim 7, at lines 2-3; and “the protein” in claim 7, at line 3; Claim 4 recites trademark/trade name “Dowex” and “IMAC” at line 5. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. Applicant is required to provide full generic chemical names of the reagents that are used in the claims since “Dowex” and “IMAC” do not tell one of ordinary skills in the art exactly what is in the compounds and such trademark can change the compositions at any time. Claim 4 recites “SP” at line 2, and it is not clear what it stands for. Applicant should spell out the full name of SP first time it appears in the claim. For the same reason, the claim is rejected for reciting “PEG” and “HIC”. Claim 6 is rejected for reciting “RVF” at line 3; claim 18 is rejected for reciting “HG2 resin” at line 2; claim 20 is rejected for reciting “MGO” at line 2; claim 39 is rejected for reciting “SP” resin. Therefore, the metes and bounds of claims are rendered vague and indefinite. The lack of clarity renders the claims very confusing and ambiguous since the resulting claims do not clearly set forth the metes and bounds of the patent protection desired. Claim 21 is rejected for depending on a cancelled claim 20. The dependency is unclear for claim 21. All other cited claims depend directly or indirectly from rejected claims and are, therefore, also, rejected under U.S.C. 112, second paragraph for the reasons set forth above. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Qiuwen Mi/ Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Feb 08, 2023
Application Filed
Dec 16, 2025
Non-Final Rejection mailed — §112
Jan 05, 2026
Applicant Interview (Telephonic)
Jan 07, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636248
A NUTRACEUTICALS FORMULATION WITH AN ENHANCED ORGANOLEPTIC PROPERTIES USED FOR SKIN CARE
2y 10m to grant Granted May 26, 2026
Patent 12636292
METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS
2y 4m to grant Granted May 26, 2026
Patent 12636336
USE OF A VEGETAL EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF A MUSCULOSKELETAL DISORDER
2y 4m to grant Granted May 26, 2026
Patent 12636308
STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS
1y 1m to grant Granted May 26, 2026
Patent 12636309
STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS
1y 1m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+49.9%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1577 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month